166. 弾性線維性仮性黄色腫 Disease details / Clinical trials / Drug dev / DR info

臨床試験数 : 19 / 薬物数 : 21 - (DrugBank : 7) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 26

薬物、開発者（Primary Sponsor）、臨床試験情報（症例登録開始年（Enrollment year）、フェーズ、ID、実施国）
Aflibercept
   University Hospital, Bonn
      2015   Phase 2   NCT02537054   Germany
CAS NO.: 7758-16-9
   Tampere university hospital
      2018   Phase 2;Phase 3   EUCTR2018-001492-20-FI   Finland
Disodium pyrophosphate
   Tampere University Hospital
      2020   Phase 2   NCT04441671   -
Disodiumpyrophosphate
   Tampere University Hospital
      2019   Phase 2   EUCTR2019-002109-24-FI   Finland
DS-1211B
   Daiichi Sankyo
      2022   Phase 2   NCT05569252   Netherlands;United States
Etidronate
   University Medical Centre Utrecht
      2023   Phase 3   EUCTR2021-000434-34-NL   Netherlands
Eylea
   Medizinische Fakultät der Universität Bonn
      2015   Phase 2   EUCTR2014-005263-33-DE   Germany
Intravitreal injection ranibizumab
   University Hospital, Bonn
      2007   Phase 2   NCT00510965   Germany
INZ-701
   Inozyme Pharma
      2024   Phase 2   NCT06462547   France;Germany;United Kingdom;United States
      2023   Phase 1   NCT05734196   Spain;United Kingdom;United States
      2022   Phase 1/Phase 2   NCT05030831   United Kingdom;United States
   Inozyme Pharma, Inc.
      2021   Phase 1;Phase 2   EUCTR2020-004000-33-FR   France
Lansolprazole
   Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)
      2018   Phase 2   EUCTR2016-004021-16-ES   Spain
Lansoprazole
   Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)
      2018   Phase 2   EUCTR2016-004021-16-ES   Spain
Lansoprazole 30MG
   Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
      2020   Phase 4   NCT04660461   Spain
Lucentis
   Department of Ophthalmology, Bonn University
      2007   Phase 2   EUCTR2006-006231-49-DE   Germany
   Novartis Pharma S.A.S
      2013   Phase 3   EUCTR2013-001421-55-FR   France
Magnesium oxide
   Mark Lebwohl
      2012   Phase 2   NCT01525875   United States
Ranibizumab
   Department of Ophthalmology, Bonn University
      2007   Phase 2   EUCTR2006-006231-49-DE   Germany
   Manhattan Eye, Ear & Throat Hospital
      2007   Phase 1/Phase 2   NCT00470977   United States
   Novartis Pharma S.A.S
      2013   Phase 3   EUCTR2013-001421-55-FR   France
Recombinant human ectonucleotide pyrophosphatase/phosphodiesterase 1 fused TO THE FC fragment OF IGG1
   Inozyme Pharma, Inc.
      2021   Phase 1;Phase 2   EUCTR2020-004000-33-FR   France
RFB002
   Novartis Pharma S.A.S
      2013   Phase 3   EUCTR2013-001421-55-FR   France
RFB002, rhufab V2
   Department of Ophthalmology, Bonn University
      2007   Phase 2   EUCTR2006-006231-49-DE   Germany
RFB002A
   Novartis Pharma S.A.S
      2013   Phase 3   EUCTR2013-001421-55-FR   France
Sodium acid pyrophosphate sapp ROR 28 food grade
   Tampere university hospital
      2018   Phase 2;Phase 3   EUCTR2018-001492-20-FI   Finland
Study treatment PPI
   Centre Hospitalier Universitaire de Nice
      2022   -   NCT04868578   France